Alpha-radiation Imaging for Neuroendocrine Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a new imaging method can detect neuroendocrine tumors, which are rare growths often originating in the digestive tract or lungs. The imaging employs a special substance called \[203Pb\]VMT-α-NET (an experimental imaging agent) to enhance tumor visibility, paving the way for a similar treatment to combat these tumors with radiation. It suits adults with a well-defined neuroendocrine tumor who have already undergone a scan showing the tumor has somatostatin receptors (specific proteins on the tumor surface). As an Early Phase 1 trial, this research focuses on understanding how the imaging agent functions in people, offering participants the opportunity to be among the first to benefit from this innovative approach.
Will I have to stop taking my current medications?
The trial requires a 24-hour discontinuation of somatostatin analogue therapy, unless your doctor thinks it's unsafe for you. If you're on long-acting somatostatin analogue treatment, it must be stopped at least 20 days before the first day of the study.
What prior data suggests that [203Pb]VMT-α-NET is safe for imaging neuroendocrine tumors?
Previous studies found that [203Pb]VMT-α-NET did not cause any serious side effects. Patients using this imaging agent experienced no severe adverse effects, suggesting it is generally well-tolerated. The imaging agent aims to detect neuroendocrine tumors using a special scan called SPECT/CT. Although this study is still in the early stages of human testing, the absence of severe side effects so far is a positive sign for safety.12345
Why are researchers excited about this trial?
Unlike traditional treatments for neuroendocrine tumors, which often involve surgery, chemotherapy, or targeted therapy, [203Pb]VMT-α-NET introduces a novel approach by using alpha-radiation imaging. This treatment utilizes a radioactive compound, [203Pb], that targets tumor cells directly, potentially allowing for more precise imaging and better dosimetry. Researchers are excited because this method not only helps in pinpointing tumor locations with high accuracy but also minimizes damage to surrounding healthy tissue. This could lead to improved outcomes and fewer side effects compared to conventional treatments.
What evidence suggests that [203Pb]VMT-α-NET is effective for identifying neuroendocrine tumors?
Research has shown that [203Pb]VMT-α-NET, a new imaging agent, could help detect neuroendocrine tumors. In early studies, its similar agent, [212Pb]VMT-α-NET, effectively slowed tumor growth and even completely eliminated some tumors. In this trial, participants will receive [203Pb]VMT-α-NET for imaging. It has been used in patients without causing serious side effects, suggesting it might be safe. The aim is to use this imaging to plan targeted treatment with [212Pb]VMT-α-NET, potentially offering a new way to treat these tumors. Early results are promising, but more research is needed to fully understand its benefits.36789
Who Is on the Research Team?
Yusuf Menda, M.D.
Principal Investigator
University of Iowa
Are You a Good Fit for This Trial?
Adults over 18 with well-differentiated neuroendocrine tumors, confirmed by pathology, that are positive for somatostatin receptors and measurable on imaging. Participants must be able to consent, follow study procedures, have a good performance status, and not have severe illnesses or conditions affecting study compliance.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Dosimetry
Participants receive a microdose of [203Pb]VMT-α-NET followed by serialized imaging and dosimetry measurements over 4 days
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- [203Pb]VMT-α-NET
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yusuf Menda
Lead Sponsor
Viewpoint Molecular Targeting
Industry Sponsor
Holden Comprehensive Cancer Center
Collaborator
Perspective Therapeutics
Industry Sponsor
National Cancer Institute (NCI)
Collaborator